BioNexus Q2 revenue rises; H1 loss, Chemrex to CDMO and Ethereum treasury add risk

BioNexus Gene Lab Corp. (PINK: BGLC)

What's happening inside:
Management is pushing growth at the Chemrex industrial-chemicals unit while trying to scale MRNA Scientific's diagnostics business. The company is reallocating Chemrex toward a biotech CDMO, adopted an Ethereum-focused treasury strategy, and signed a non‑binding term sheet with Fidelion Diagnostics for MRD commercialization in SE Asia (July 2025). Governance actions include a March 2025 1-for-10 reverse split, a new CFO (appointed June 17, 2025), and remediation steps after the audit committee flagged control deficiencies at Chemrex.

Key points & key stats (facts from the 10‑Q)
- Q2 2025 revenue: $2,260,253 (+14.5% vs Q2 2024).
- 6 months 2025 revenue: $4,397,328 (+0.9% vs H1 2024).
- Q2 2025 gross profit: $368,022; gross margin ~16.3% (management said +170 bps YoY).
- Net (loss)/profit attributable to common shareholders: Q2 2025 $(616,172); Q2 2024 $199,104. Six months 2025 $(1,239,499); six months 2024 $95,347.
- EPS basic & diluted: Q2 2025 $(0.343); six months 2025 $(0.690).
- Cash and cash equivalents (end of period): $1,537,189. Fixed deposits: $2,244,699. Investments in equity securities: $1,248,688.
- Management "total liquidity" (cash + fixed deposits + investments + receivables net) ≈ $6.88 million (company metric).
- Trade receivables gross: $2,346,753; allowance: $494,668; net trade receivables: $1,852,085.
- Working capital: $4,621,505. Total assets: $9,421,205. Total liabilities: $1,899,168. Total stockholders' equity: $7,522,037.
- Cash used in operating activities (six months): $(1,561,979). Net change in cash: $(1,349,777) for H1 2025.
- Significant expense jump: Sales & marketing Q2 2025 $608,427 vs Q2 2024 $136,494; H1 2025 $1,149,122 vs H1 2024 $290,365.
- Fair value (loss) on equity investments: Q2 2025 $(51,002); H1 2025 $(119,499).
- Allowance / credit events: reversal of expected credit losses Q2 2025 $69,759 vs Q2 2024 $552,663; provision for expected credit losses H1 2025 $(40,124).
- Major customer concentration (Q2 2025): Customer A = $250,240 (11% of Q2 revenue) with accounts receivable $317,314 at period end.
- Major suppliers: Vendor A purchases H1 2025 $1,081,275 (29.34% of purchases); accounts payable to Vendor A $647,890.

Income statement - positives
- Top-line growth in the quarter (Q2 +14.5%) driven by Chemrex trading volume.
- Gross profit improved: Q2 gross profit $368k (+27.5% YoY) and H1 gross profit up 8.8% YoY - shows product mix/pricing helped margins.
- Management reduced some credit loss provisioning activity versus the prior year (big reversal in 2024 normalized), indicating improved collections versus prior periods.
- Other strategic income sources (dividends, investment gains) remain available as liquidity cushions when realized.

Income statement - negatives
- Large operating loss: Q2 operating loss $(611,293); H1 operating loss $(1,229,711).
- Heavy increase in operating expenses, principally sales & marketing and G&A - S&M jumped sharply (Q2: $608k vs $136k prior) and drove most of the swing to loss.
- Other income collapsed YoY (Q2 $209k vs $730k in 2024) mainly because large reversal of expected credit losses in 2024 did not repeat; interest/dividend income also lower.
- Fair value volatility on equity investments produced losses (H1 $(119k)), which hit earnings directly.
- Cash burn from operations is meaningful: $(1.56M) in H1 2025 despite positive total liquidity on the balance sheet.
- Receivables concentration and allowance: trade receivables remain high (gross $2.35M) with a $494k allowance - credit risk and concentration (single customer 11% of Q2 revenue) are clear exposures.

Operational and governance risks
- Audit committee identified significant deficiency in internal controls at Chemrex (documentation, delegation, timeliness); remediation plan is in progress but not complete.
- Concentration risk with key suppliers and customers (Vendor A large supplier; Customer A ~11% of Q2 revenue).
- Foreign exchange volatility materially affects reported results - the company recorded large FX translation gains in 2025 but this can swing the other way.
- Crypto/treasury strategy risk: Board approved an Ethereum treasury approach - market volatility, custody and accounting (GAAP fair value) can increase reported earnings volatility and operational risk.
- Several strategic initiatives are still conditional/non-binding (Fidelion term sheet, Chemrex CDMO transition) - execution risk and capital needs remain.

Recent corporate developments to watch
- Ethereum treasury strategy and ML Tech partnership announced March 2025 (monitor for any crypto purchases and related accounting impacts).
- Non-binding Fidelion term sheet (July 30, 2025) for MRD commercialization - if executed could materially change diagnostics roadmap and margins but remains conditional.
- Board approved repositioning of Chemrex to CDMO (July 31, 2025) and authorized up to MYR 10 million for the transition - requires capital deployment and successful GMP execution.
- Governance moves: reverse stock split (April 2025) restored Nasdaq compliance; new CFO appointed June 17, 2025; remediation actions implemented for subsidiary controls.

Bottom line - straight takeaway
BioNexus (PINK: BGLC) has real revenue traction in its Chemrex trading business and a sizable liquidity cushion of cash, deposits, investments and receivables (~$6.9M by management's metric). But the P&L shows a clear transition period: rapidly rising operating expenses (notably compensation / S&M), fair‑value losses, and operating cash outflows produced a material H1 net loss of $(1.24M). Execution risks (Chemrex internal controls, CDMO conversion, Fidelion deal) and the new Ethereum treasury strategy add upside if managed well - but also add volatility and execution risk. Watch quarterly cash burn, receivable collections (allowance trends), S&M spend discipline, and any realized gains/losses from investments or crypto holdings.